KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Capital Expenditures: 2011-2022

Historic Capital Expenditures for TherapeuticsMD (TXMD) over the last 9 years, with Jun 2022 value amounting to -$21,000.

  • TherapeuticsMD's Capital Expenditures fell 151.22% to -$21,000 in Q2 2022 from the same period last year, while for Jun 2022 it was -$8,000, marking a year-over-year decrease of 102.81%. This contributed to the annual value of $34,000 for FY2021, which is 83.57% down from last year.
  • Latest data reveals that TherapeuticsMD reported Capital Expenditures of -$21,000 as of Q2 2022, which was down 150.00% from $42,000 recorded in Q1 2022.
  • TherapeuticsMD's Capital Expenditures' 5-year high stood at $996,909 during Q3 2019, with a 5-year trough of -$70,000 in Q3 2021.
  • Moreover, its 3-year median value for Capital Expenditures was $21,000 (2020), whereas its average is $29,111.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 4,745.24% in 2019, then slumped by 638.46% in 2021.
  • Over the past 5 years, TherapeuticsMD's Capital Expenditures (Quarterly) stood at $150,745 in 2018, then surged by 139.20% to $360,587 in 2019, then crashed by 53.41% to $168,000 in 2020, then tumbled by 638.46% to -$70,000 in 2021, then plummeted by 151.22% to -$21,000 in 2022.
  • Its Capital Expenditures stands at -$21,000 for Q2 2022, versus $42,000 for Q1 2022 and -$70,000 for Q3 2021.